]. R. Références1, D. Anton, H. J. Frohne, E. M. Pf-nder, and . Bernard, Plantes à risques un ouvrage destiné aux pharmaciens, aux médecins, toxicologues et biologistes. Paris; Cachan: Éd Cannabis: approches thérapeutiques contemporaines, Cannabis en médecine un guide pratique des applications médicales du cannabis et du THC, 2008.

W. A. Devane, Isolation and structure of a brain constituent that binds to the cannabinoid receptor, Science, vol.258, issue.5090, pp.18-1992, 19469.
DOI : 10.1126/science.1470919

«. Tiziana-bisogno, A. Ligresti, and V. D. Marzo, Aspects moléculaires, cellulaires et physiologiques des effets du cannabis The endocannabinoid signalling system Biochemical aspects, Académie des sciences (France) Endocannabinoid 2-Arachidonyl Glycerol Is a Full Agonist through Human Type 2 Cannabinoid Receptor: Antagonism by Anandamide, pp.1045-1050, 1997.

V. Stephen, K. Mahler, . Smith, C. Kent, and . Berridge, « Endocannabinoid Hedonic Hotspot for Sensory Pleasure: Anandamide in Nucleus Accumbens Shell Enhances Liking of a Sweet Reward, Neuropsychopharmacology, vol.9, pp.2267-2278, 2007.

D. Piomelli and «. Thc, THC: moderation during implantation, Nature Medicine, vol.10, issue.1, pp.19-20, 2004.
DOI : 10.1038/nm0104-19

R. Mona, H. Anthony, . Taylor, C. Justin, and . Konje, « The relationship between plasma levels of the endocannabinoid, anandamide, sex steroids, and gonadotrophins during the menstrual cycle, Fertility and Sterility, 2010.

L. De-petrocellis, D. Melck, A. Palmisano, T. Bisogno, C. Laezza et al., The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation, Proc. Natl. Acad. Sci, pp.14-8375, 1998.
DOI : 10.1073/pnas.95.14.8375

. Mechoulam, Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors, Biochemical Pharmacology, vol.50, issue.1, pp.83-90
DOI : 10.1016/0006-2952(95)00109-D

T. Sugiura, N. Yoshinaga, and E. K. Waku, Rapid generation of 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand, in rat brain after decapitation, Neuroscience Letters, vol.297, issue.3, pp.175-178, 2001.
DOI : 10.1016/S0304-3940(00)01691-8

V. Evgueni, . Berdyshev, C. Patricia, R. J. Schmid, . Krebsbach et al., Activation of PAF receptors results in enhanced synthesis of 2-arachidonoylglycerol (2-AG) in immune cells, The FASEB Journal, pp.2171-2178

K. Nithipatikom, « 2-arachidonoylglycerol: a novel inhibitor of androgenindependent prostate cancer cell invasion. », Cancer Res, pp.8826-8856

. Kunos, Biosynthesis and inactivation of the endocannabinoid 2-arachidonoylglycerol in circulating and tumoral macrophages, Eur. J. Biochem, vol.264, issue.1, pp.258-267, 1999.

A. Ligresti, E. Morera, M. Van-der-stelt, K. Monory, B. Lutz et al., Further evidence for the existence of a specific process for the membrane transport of anandamide, Biochemical Journal, vol.380, issue.1, pp.265-272, 2004.
DOI : 10.1042/bj20031812

M. L. López-rodríguez, A. Viso, S. Ortega-gutiérrez, C. J. Fowler, G. Tiger et al., Design, Synthesis, and Biological Evaluation of New Inhibitors of the Endocannabinoid Uptake:?? Comparison with Effects on Fatty Acid Amidohydrolase, Journal of Medicinal Chemistry, vol.46, issue.8, pp.1512-1522, 2003.
DOI : 10.1021/jm0210818

D. Petrocellis, L. Bisogno, T. Maccarrone, M. Davis, and J. , The Activity of Anandamide at Vanilloid VR1 Receptors Requires Facilitated Transport across the Cell Membrane and Is Limited by Intracellular Metabolism, Journal of Biological Chemistry, vol.276, issue.16, pp.12856-63
DOI : 10.1074/jbc.M008555200

T. J. Tognetto, J. F. Petros, C. J. Krey, and . Chu, et others, « An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid VR1 receptors, Proc. Natl

M. Patricelli and B. Cravatt, Clarifying the Catalytic Roles of Conserved Residues in the Amidase Signature Family, Journal of Biological Chemistry, vol.275, issue.25, 2000.
DOI : 10.1074/jbc.M001607200

. Goparaju, Enzymes of porcine brain hydrolyzing 2-arachidonoylglycerol, an endogenous ligand of cannabinoid receptors, Biochemical Pharmacology, vol.57, issue.4, pp.417-440, 1999.
DOI : 10.1016/S0006-2952(98)00314-1

. Gulyas, Segregation of two endocannabinoid-hydrolyzing enzymes into preand postsynaptic compartments in the rat hippocampus, cerebellum and amygdala », Eur J Neurosc, pp.441-58, 2004.

K. R. Kozak and L. J. Marnett, Oxidative metabolism of endocannabinoids, Prostaglandins, Leukotrienes and Essential Fatty Acids (PLEFA), vol.66, issue.2-3, pp.211-220, 2002.
DOI : 10.1054/plef.2001.0359

M. Stelt, J. Van-kuik, M. Bari, G. Van-zadelhoff, B. Leeflang et al., Oxygenated metabolites of anandamide and 2-arachidonoylglycerol: conformational analysis and interaction with cannabinoid receptors, membrane transporter, and fatty acid amide hydrolase, J Med Chem, vol.20, pp.3709-3724

S. J. Craib, H. C. Ellington, R. G. Pertwee, and R. A. Ross, A possible role of lipoxygenase in the activation of vanilloid receptors by anandamide in the guinea-pig bronchus, British Journal of Pharmacology, vol.400, issue.1, pp.30-37, 2001.
DOI : 10.1038/sj.bjp.0704223

K. Kozak, 15-Lipoxygenase Metabolism of 2-Arachidonylglycerol. GENERATION OF A PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR alpha AGONIST, Journal of Biological Chemistry, vol.277, issue.26, pp.23278-86
DOI : 10.1074/jbc.M201084200

«. Ellington, Pharmacological characterization of the anandamide cyclooxygenase metabolite: prostaglandin E2 ethanolamide, J. Pharmacol. Exp. Ther, vol.301, issue.3, pp.900-907, 2002.

I. Matias, Prostaglandin Ethanolamides (Prostamides): In Vitro Pharmacology and Metabolism, Journal of Pharmacology and Experimental Therapeutics, vol.309, issue.2, pp.745-57
DOI : 10.1124/jpet.103.061705

L. M. Bornheim, K. Y. Kim, B. L. Chen, and M. A. Correia, The Effect of Cannabidiol on Mouse Hepatic Microsomal Cytochrome P450-Dependent Anandamide Metabolism, Biochemical and Biophysical Research Communications, vol.197, issue.2, pp.740-746, 1993.
DOI : 10.1006/bbrc.1993.2541

L. M. Bornheim, K. Y. Kim, B. Chen, and M. A. Correia, Microsomal cytochrome P450-mediated liver and brain anandamide metabolism, Microsomal cytochrome P450- mediated liver and brain anandamide metabolism, pp.677-686, 1995.
DOI : 10.1016/0006-2952(95)00177-2

W. Karl, . Hilig, G. Paull, and . Mahlberg, « A chemotaxonomic analysis of cannabinoid variation in Cannabis (Cannabaceae) », Botany, pp.101-2014

K. Laine, Comparison of the enzymatic stability and intraocular pressure effects of 2-arachidonylglycerol and noladin ether, a novel putative endocannabinoid, Invest Ophthalmol Vis Sci, pp.3216-3238

Y. Sun, S. Alexander, and A. Bennett, Cannabinoid activation of PPAR??; a novel neuroprotective mechanism, British Journal of Pharmacology, vol.400, issue.5, pp.734-743
DOI : 10.1038/sj.bjp.0707478

«. Dopamine and @. Nada, CAS 199875-69-9) (Inchi key MVVPIAAVGAWJNQ-DOFZRALJSA-N) || Cayman Chemical | Supplier ». [En ligne]. Disponible sur: https://www.caymanchem.com, pp.27-2015

«. Sherry-shu-jung, H. Heather, and B. Bradshaw, The biosynthesis of N-arachidonoyl dopamine (NADA), a putative endocannabinoid and endovanilloid, via conjugation of arachidonic acid with dopamine, Prostaglandins, Leukotrienes and Essential Fatty Acids, vol.81, pp.291-301, 2009.

D. Sagar, TRPV1 and CB1 receptor-mediated effects of the endovanilloid/endocannabinoid N-arachidonoyl-dopamine on primary afferent fibre and spinal cord neuronal responses in the rat, European Journal of Neuroscience, vol.59, issue.1, pp.175-84, 2004.
DOI : 10.1016/0306-4522(94)90218-6

S. E. O-'sullivan, D. A. Kendall, and M. D. Rand, « Vascular effects of delta 9- tetrahydrocannabinol (THC), anandamide and N -arachidonoyldopamine (NADA) in the rat isolated aorta, pp.507-211, 2005.

M. Bernardi, M. Molinari, N. B. Maccarrone, and . Mercuri, « N-Arachidonoyl-dopamine tunes synaptic transmission onto dopaminergic neurons by activating both cannabinoid and vanilloid receptors, pp.32-298, 2007.

S. M. Huang and J. M. Walke, « Enhancement of spontaneous and heat-evoked activity in spinal nociceptive neurons by the endovanilloid, NADA), vol.95, pp.1207-1212, 2006.

«. File, Arachidonoyl ethanolamine (Virodhamine or OAE) Type.jpg -Wikimedia Commons ». [En ligne] Disponible sur: https://commons.wikimedia.org/wiki/File:Endocannabinoid_Structure_-_O [47] Porter AC et al, « Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor, J Pharmacol Exp Ther, pp.1020-1024

E. Gkoumassi, B. Dekkers, and S. Nelemans, Virodhamine and CP55,940 modulate cAMP production and IL-8 release in human bronchial epithelial cells, British Journal of Pharmacology, vol.23, issue.7, pp.1041-1048
DOI : 10.1038/sj.bjp.0707320

H. Sharir, The Endocannabinoids Anandamide and Virodhamine Modulate the Activity of the Candidate Cannabinoid Receptor GPR55, Journal of Neuroimmune Pharmacology, vol.284, issue.18, p.2012
DOI : 10.1007/s11481-012-9351-6

R. Piñeiro and M. Falasca, « Lysophosphatidylinositol signalling: new wine from an old bottle, Biochim Biophys Acta, pp.694-705

V. Gangadharan, D. Selvaraj, M. Kurejova, C. Njoo, S. Gritsch et al., A novel biological role for the phospholipid lysophosphatidylinositol in nociceptive sensitization via activation of diverse Gprotein signalling pathways in sensory nerves in vivo, Pain, pp.2801-2813

Y. Gaoni, R. Mechoulam, and . Isolation, Isolation, Structure, and Partial Synthesis of an Active Constituent of Hashish, Journal of the American Chemical Society, vol.86, issue.8, pp.1646-1647, 1964.
DOI : 10.1021/ja01062a046

«. Toxnet and ». , Disponible sur: http://toxnet.nlm.nih.gov/cgi- bin/sis/search2/f?, Consulté le, pp.18-2014

«. User, Hbarton3/Cannabidiol Effects on Epilepsy -Wikipedia, the free encyclopedia ». [En ligne]. Disponible sur: https://en.wikipedia.org/wiki, pp.27-2015

E. Ryberg, The orphan receptor GPR55 is a novel cannabinoid receptor, British Journal of Pharmacology, vol.96, issue.69, pp.1092-1101
DOI : 10.1038/sj.bjp.0707460

E. B. Russo, A. Burnett, B. Hall, and K. K. Parker, Agonistic Properties of Cannabidiol at 5-HT1a Receptors, Neurochemical Research, vol.54, issue.2, pp.1037-1043
DOI : 10.1007/s11064-005-6978-1

M. Kathmann, K. Flau, A. Redmer, and C. Tränkle, Eberhard Schlicker, « Cannabidiol is an allosteric modulator at mu-and delta-opioid receptors », Archives of Pharmacology, pp.18-2006

. Disponible-sur, is-cannabigerol-cbg-the-ultimate- cannabinoid, Consulté le, pp.27-2014, 2013.

S. Maione, Non-psychoactive cannabinoids modulate the descending pathway of antinociception in anaesthetized rats through several mechanisms of action, British Journal of Pharmacology, vol.159, issue.1
DOI : 10.1111/j.1476-5381.2010.01063.x

A. Angelo and . Izzo, Inhibitory effect of cannabichromene, a major non-psychotropic cannabinoid extracted from Cannabis sativa, on inflammation-induced hypermotility in mice », Br J Pharmacol, pp.1444-1460

N. Shinjyo and V. D. Marzo, The effect of cannabichromene on adult neural stem/progenitor cells, Neurochemistry International, vol.63, issue.5, pp.432-437
DOI : 10.1016/j.neuint.2013.08.002

«. Tetrahydrocannabivarin-wikipedia, the free encyclopedia ». [En ligne] Disponible sur: https://en.wikipedia.org/wiki, Tetrahydrocannabivarin.Consulté, vol.le, pp.27-2015

D. Compton, Aminoalkylindole Analogs: Cannabimimetic Activity of a Class of Compounds Structurally Distinct from ?9, Tetrahydrocannabinol » Journal of Pharmacology and Experimental Therapeutics, pp.1118-1126, 1992.

«. File, 212-2-2D-skeletal.svg -Wikimedia Commons ». [En ligne] Disponible sur: https://commons.wikimedia.org/wiki/File:WIN_55,212-2-2D-skeletal, pp.27-2015

«. Win-55, 212-2 -BML-CR105 -Enzo Life Sciences ». [En ligne] Disponible sur, www.enzolifesciences.com/BML-CR105/win-55-212-2/. [Consulté le, pp.22-2014

«. Jwh, CAS 209414-07-3) || Cayman Chemical | Supplier ». [En ligne] Disponible sur: https://www.caymanchem.com/app/template/Product.vm/catalog, Consulté le, pp.22-2014, 10900.

W. A. Devane, A novel probe for the cannabinoid receptor, Journal of Medicinal Chemistry, vol.35, issue.11, pp.2065-2069, 1992.
DOI : 10.1021/jm00089a018

«. File, HU-210 chemical structure.png -Wikimedia Commons ». [En ligne] Disponible sur: https://commons.wikimedia.org/wiki/File:HU-210_chemical_structure.png, Consulté le, pp.27-2015

R. K. Razdan, The Total Synthesis of Cannabinoids, Total Synthesis of Natural Products, pp.185-262, 1981.
DOI : 10.1002/9780470129678.ch2

«. Cp, 940 -Wikipedia, the free encyclopedia ». [En ligne] Disponible sur: https://en.wikipedia.org/wiki, pp.27-2015

«. Dailymed-dronabinol-dronabinol-capsule and ». , En ligne] Disponible sur: http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a0409d82-a61e-4b9e-8717- ced299ccedb2, Consulté le, pp.30-2014

M. Heim, W. Romer, and W. Queisser, Clinical Experience with Levonantradol Hydrochloride in the Prevention of Cancer Chemotherapy-Induced Nausea and Vomiting, The Journal of Clinical Pharmacology, vol.300, issue.S1, pp.86-89
DOI : 10.1002/j.1552-4604.1981.tb02580.x

C. Cronin, S. Sallan, R. Gelber, V. Lucas, J. Laszlo et al., Antiemetic Effect of Intramuscular Levonantradol in Patients Receiving Anticancer Chemotherapy, The Journal of Clinical Pharmacology, vol.21, issue.S1, pp.43-50
DOI : 10.1002/j.1552-4604.1981.tb02572.x

«. Cesamet, Nabilone Capsules) Drug Information: Description, User Reviews, Drug Side Effects, Interactions -Prescribing Information at RxList ». [En ligne]. Disponible sur, pp.2-2015

«. Cannabis, M. Cesamet®, S. Blog-du-growshop-alchimia, and ». , En ligne] Disponible sur: http://www.alchimiaweb.com/blogfr/cannabismedicaments-cesamet-marinol-sativex, Consulté le, pp.2-2015

«. Nabilone-wikipedia, the free encyclopedia ». [En ligne] Disponible sur: https://en.wikipedia.org/wiki, pp.27-2015

«. Tablets, Generic Acomplia) -Uses, Dosage and Side effects | Medical Cheat Sheets ». [En ligne] Disponible sur: http://medicalcheatsheets.blogspot.fr/2011/03/rimonabant-tablets-generic-acomplia.html, Consulté le, pp.27-2015

«. Gwpharma-sativex and ». , En ligne] Disponible sur, pp.20-2014

«. Gwpharma-sativex and R. ». , En ligne] Disponible sur, pp.22-2014

M. Elphick and M. Egertová, The neurobiology and evolution of cannabinoid signalling, Philosophical Transactions of the Royal Society B: Biological Sciences, vol.356, issue.1407, pp.381-408
DOI : 10.1098/rstb.2000.0787

P. Pacher, S. Bátkai, and G. Kunos, The Endocannabinoid System as an Emerging Target of Pharmacotherapy, Pharmacological Reviews, vol.58, issue.3, pp.389-462
DOI : 10.1124/pr.58.3.2

«. Trpv1, Pain, Peppers, and Prostaglandins | Article Library || Cayman Chemical | Supplier ». [En ligne]. Disponible sur: https, pp.22-2015

A. Mckillop, B. Moran, Y. Wahab, and P. Flatt, « Evaluation of the insulin releasing and antihyperglycaemic activities of GPR55 lipid agonists using clonal betacells , isolated pancreatic islets and mice », Br J Pharmacol, pp.978-990

. Bifulco, . Laezza, . Gazzerro, and . Pentimalli, Endocannabinoids as emerging suppressors of angiogenesis and tumor invasion (Review), Oncology Reports, vol.17, issue.4, pp.813-816, 2007.
DOI : 10.3892/or.17.4.813

M. Guzmán and C. Sánchez, Control of the cell survival/death decision by cannabinoids, Journal of Molecular Medicine, vol.78, issue.11, pp.613-625, 2001.
DOI : 10.1007/s001090000177

B. Romano, F. Borrelli, E. Pagano, M. Cascio, R. Pertwee et al., Inhibition of colon carcinogenesis by a standardized Cannabis sativa extract with high content of cannabidiol, Phytomedicine, vol.21, issue.5, 2013.
DOI : 10.1016/j.phymed.2013.11.006

M. P. Endsley, R. Thill, I. Choudhry, C. L. Williams, A. Kajdacsy-balla et al., Expression and function of fatty acid amide hydrolase in prostate cancer, International Journal of Cancer, vol.86, issue.Part 1, pp.1318-1326, 2008.
DOI : 10.1002/ijc.23674

«. Cancer-du-sein-symptômes-et-traitement and ». Sante-medecine, [En ligne] Disponible sur: http://sante-medecine.commentcamarche.net/contents/132-cancer-du-sein- symptomes-et-traitement, Consulté le, pp.26-2014

N. M. Bennington, R. J. Lee, P. Debs, and . Desprez, « Id-1 as a molecular target in therapy for breast cancer cell invasion and metastasis, Proc. Natl. Acad. Sci. U. S. A, vol.100, issue.23, pp.13543-13548, 2003.

S. D. Mcallister, R. T. Christian, M. P. Horowitz, and A. Garcia, Cannabidiol as a novel inhibitor of Id-1 gene expression in aggressive breast cancer cells, Molecular Cancer Therapeutics, vol.6, issue.11, pp.2921-2927, 2007.
DOI : 10.1158/1535-7163.MCT-07-0371

«. Gliome-définition and ». , En ligne] Disponible sur: http://santemedecine .commentcamarche.net/faq/13389-gliome-definition, Consulté le, pp.27-2014

S. Torres, A Combined Preclinical Therapy of Cannabinoids and Temozolomide against Glioma, Molecular Cancer Therapeutics, vol.10, issue.1, pp.90-103
DOI : 10.1158/1535-7163.MCT-10-0688

«. Gwpharma-oncology and ». , En ligne] Disponible sur, pp.25-2014

«. Gwpharma-rationale and ». Preclinical, En ligne] Disponible sur, pp.3-2015

A. Izzo, F. Borrelli, R. Capasso, D. Marzo, V. Mechoulam et al., Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb, Trends in Pharmacological Sciences, vol.30, issue.10, pp.512-539
DOI : 10.1016/j.tips.2009.07.006

E. Carrier, J. Auchampach, and C. Hillard, Inhibition of an equilibrative nucleoside transporter by cannabidiol: A mechanism of cannabinoid immunosuppression, Proceedings of the National Academy of Sciences, vol.103, issue.20
DOI : 10.1073/pnas.0511232103

N. Jones, WITHDRAWN: Cannabidiol exerts anti-convulsant effects in animal models of temporal lobe and partial seizures, Seizure, pp.344-52
DOI : 10.1016/j.seizure.2010.12.002

I. Karniol, I. Shirakawa, N. Kasinski, A. Pfeferman, and E. Carlini, « Cannabidiol interferes with the effects of delta 9 -tetrahydrocannabinol in man », Eur J Pharmacol, pp.172-179

«. Cannabis-et-glaucome-sensi and ». Seeds, En ligne] Disponible sur: http://sensiseeds.com/fr/blog/cannabis-et-glaucome, Consulté le, pp.3-2015

«. Qu-'est-ce-que-le-glaucome-?-|-le-glaucome and ». , En ligne] Disponible sur: http://www.leglaucome.fr/sinformer/quest-ce-que-le-glaucome, Consulté le, pp.3-2015

«. Fmpmc-ps-anatomie-pathologique-niveau and P. ». , En ligne] Disponible sur, pp.5-2015

W. Zhu, H. Friedman, and T. Klein, « Delta9-tetrahydrocannabinol induces apoptosis in macrophages and lymphocytes: involvement of Bcl-2 and caspase-1, 1998.

Y. Do, R. Mckallip, M. Nagarkatti, and P. Nagarkatti, Activation through cannabinoid receptors 1 and 2 on dendritic cells triggers NF-kappaB-dependent apoptosis: novel role for endogenous and exogenous cannabinoids in immunoregulation, J Immunol, pp.2373-82

Y. Do, R. Mckallip, M. Nagarkatti, and P. Nagarkatti, Activation through cannabinoid receptors 1 and 2 on dendritic cells triggers NF-kappaB-dependent apoptosis: novel role for endogenous and exogenous cannabinoids in immunoregulation, J Immunol

C. Lee, S. Wey, M. Liao, W. Hsu, and H. Wu, A comparative study on cannabidiol-induced apoptosis in murine thymocytes and EL-4 thymoma cells, International Immunopharmacology, vol.8, issue.5, pp.732-772
DOI : 10.1016/j.intimp.2008.01.018

F. Molina-holgado, E. Molina-holgado, C. Guaza, and N. Rothwell, Role of CB1 and CB2 receptors in the inhibitory effects of cannabinoids on lipopolysaccharide-induced nitric oxide release in astrocyte cultures, Journal of Neuroscience Research, vol.256, issue.6, pp.829-865
DOI : 10.1002/jnr.10165

J. Croxford, P. G. Jackson, S. Ledent, C. Giovannoni, G. Pertwee et al., Cannabinoid-mediated neuroprotection, not immunosuppression, may be more relevant to multiple sclerosis, Journal of Neuroimmunology, vol.193, issue.1-2, pp.120-129
DOI : 10.1016/j.jneuroim.2007.10.024

T. Klein, C. Newton, N. Nakachi, and H. Friedman, « Delta 9-tetrahydrocannabinol treatment suppresses immunity and early IFN-gamma, IL-12, and IL-12 receptor beta 2 responses to Legionella pneumophila infection, J Immunol, pp.6461-6467

M. Srivastava, B. Srivastava, and B. Brouhard, « Delta9 tetrahydrocannabinol and cannabidiol alter cytokine production by human immune cells. -PubMed -NCBI, Immunopharmacology, pp.179-85

R. Puffenbarger, A. Boothe, and G. Cabral, « Cannabinoids inhibit LPS-inducible cytokine mRNA expression in rat microglial cells, Glia, pp.58-69

J. Parker, F. Atez, R. Rossetti, A. Skulas, R. Patel et al., Suppression of human macrophage interleukin-6 by a nonpsychoactive cannabinoid acid, Rheumatology International, vol.100, issue.7, pp.631-636
DOI : 10.1007/s00296-007-0489-0

P. Valk, a natural ligand for the peripheral cannabinoid receptor is a novel synergistic growth factor for hematopoietic cells, pp.1448-57

C. Rockwell, N. Snider, J. Thompson, V. Heuvel, J. Kaminski et al., « Interleukin-2 suppression by 2-arachidonyl glycerol is mediated through peroxisome proliferator-activated receptor gamma independently of cannabinoid receptors 1 and, Mol Pharmacol, issue.2, pp.101-112

L. Mestre, F. Correa, A. Arévalo-martín, E. Molina-holgado, M. Valenti et al., Pharmacological modulation of the endocannabinoid system in a viral model of multiple sclerosis, Journal of Neurochemistry, vol.118, issue.6, pp.1327-1366
DOI : 10.1111/j.1471-4159.2004.02979.x

M. Maccarrone, H. Valensise, M. Bari, N. Lazzarin, C. Romanini et al., Progesterone Up-Regulates Anandamide Hydrolase in Human Lymphocytes: Role of Cytokines and Implications for Fertility, The Journal of Immunology, vol.166, issue.12, pp.7183-7192
DOI : 10.4049/jimmunol.166.12.7183

P. Nagarkatti, Cannabinoids as novel anti-inflammatory drugs, Future Medicinal Chemistry, vol.1, issue.7, pp.1333-1349
DOI : 10.4155/fmc.09.93

S. Ghosh, A. Preet, J. Groopman, and R. Ganju, Cannabinoid receptor CB2 modulates the CXCL12/CXCR4-mediated chemotaxis of T lymphocytes, Molecular Immunology, vol.43, issue.14, pp.2169-79
DOI : 10.1016/j.molimm.2006.01.005

A. Iglesias, J. Bauer, T. Litzenburger, A. Schubart, C. Linington et al., T- and B-cell responses to myelin oligodendrocyte glycoprotein in experimental autoimmune encephalomyelitis and multiple sclerosis, Glia, vol.31, issue.2, p.2001
DOI : 10.1002/glia.1111

A. Arévalo-martín, D. García-ovejero, O. Gómez, A. Rubio-araiz, B. Navarro-galve et al., « CB2 cannabinoid receptors as an emerging target for demyelinating diseases: from neuroimmune interactions to cell replacement strategies », Br J Pharmacol, pp.216-241

A. Sánchez, P. González-pérez, I. Galve-roperh, and A. García-merino, R-(+)-[2,3-Dihydro-5-methyl-3-(4-morpholinylmethyl)-pyrrolo-[1,2,3-de]-1,4-benzoxazin-6-yl]-1-naphtalenylmethanone (WIN-2) ameliorates experimental autoimmune encephalomyelitis and induces encephalitogenic T cell apoptosis: Partial involvement of the CB2 receptor, Biochemical Pharmacology, vol.72, issue.12, pp.1697-706
DOI : 10.1016/j.bcp.2006.08.018

W. Sheng, S. Hu, X. Min, G. Cabral, J. Lokensgard et al., « Synthetic cannabinoid WIN55,212-2 inhibits generation of inflammatory mediators by IL-1beta- stimulated human astrocytes, Glia, pp.211-220

J. Palazuelos, N. Davoust, B. Julien, E. Hatterer, T. Aguado et al., The CB2 Cannabinoid Receptor Controls Myeloid Progenitor Trafficking: INVOLVEMENT IN THE PATHOGENESIS OF AN ANIMAL MODEL OF MULTIPLE SCLEROSIS, Journal of Biological Chemistry, vol.283, issue.19, pp.13320-13329
DOI : 10.1074/jbc.M707960200

G. Arthur and . Pratt, « Current concepts in the pathogenesis of early rheumatoid arthritis, Best Pract Res Clin Rheumatol, pp.37-48

A. M. Malfait, The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis, Proceedings of the National Academy of Sciences, vol.97, issue.17, pp.9561-9566
DOI : 10.1073/pnas.160105897

R. Zurier, R. Rossetti, S. Burstein, and B. Bidinger, « Suppression of human monocyte interleukin-1beta production by ajulemic acid, a nonpsychoactive cannabinoid, Biochem Pharmacol, pp.649-55

K. George, L. Saltman, G. Stein, J. Lian, and R. Zurier, Ajulemic acid, a nonpsychoactive cannabinoid acid, suppresses osteoclastogenesis in mononuclear precursor cells and induces apoptosis in mature osteoclast-like cells, Journal of Cellular Physiology, vol.65, issue.3, pp.714-734
DOI : 10.1002/jcp.21263

N. Amere, A. H. Battista, L. A. Lichtman, and . Gauson, et others, « ?8-Tetrahydrocannabivarin prevents hepatic ischaemia/reperfusion injury by decreasing oxidative stress and inflammatory responses through cannabinoid CB2 receptors, Br. J. Pharmacol, vol.165, issue.8, pp.2450-2461, 2012.

«. Maladie-de-parkinson and ». , Disponible sur: http://www.inserm.fr/thematiques/neurosciences-sciences-cognitives-neurologiepsychiatrie/dossiers-d-information/maladie-de-parkinson, Consulté le, pp.4-2014

K. Chaudhuri, D. G. Healy, and A. H. Schapira, Non-motor symptoms of Parkinson's disease: diagnosis and management, The Lancet Neurology, vol.5, issue.3, pp.235-245, 2006.
DOI : 10.1016/S1474-4422(06)70373-8

P. Dr and . Boulu, Parkinson: chiffres clés et prevalence Atlas neurologique -OMS, 2004.

U. Oertel, K. Siebert, E. R. Berger, and . Dodel, « Prevalence and incidence of Parkinson's disease in Europe, Eur. Neuropsychopharmacol, vol.15, issue.4, pp.473-490, 2005.

. Mme-anne-taupignon, UFR Pharmacie-Institut des maladies neurodégénératives, Cours de 2ème année de pharmacie, Anatomie-Physiologie, pp.2011-2010

M. Brusa and P. Pierantozzi, Stanzione, et others, « High endogenous cannabinoid levels in the cerebrospinal fluid of untreated Parkinson's disease patients, Ann. Neurol, vol.57, issue.5, pp.777-779, 2005.

C. García, C. Palomo-garo, M. García-arencibia, J. Ramos, and R. Pertwee, -THCV in animal models of Parkinson's disease, British Journal of Pharmacology, vol.146, issue.1074, pp.1495-1506, 2011.
DOI : 10.1111/j.1476-5381.2011.01278.x

URL : https://hal.archives-ouvertes.fr/in2p3-00121621

I. Dennis, B. J. Whalley, and G. J. Stephens, S]GTP??S binding in mouse brain cerebellum and piriform cortex membranes, British Journal of Pharmacology, vol.77, issue.6, pp.1349-1358, 2008.
DOI : 10.1038/bjp.2008.190

Y. Ma, S. E. Weston, B. J. Whalley, and G. J. Stephens, -tetrahydrocannabivarin modulates inhibitory neurotransmission in the cerebellum, British Journal of Pharmacology, vol.25, issue.Suppl. 1, pp.204-215, 2008.
DOI : 10.1038/bjp.2008.57

URL : https://hal.archives-ouvertes.fr/hal-00018610

R. G. Pertwee, « The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: ?9-tetrahydrocannabinol, cannabidiol and ?9-tetrahydrocannabivarin, Br. J. Pharmacol, vol.153, issue.2, 2008.

M. Starks, Marijuana chemistry: genetics, processing & potency, 1990.

M. A. Elsohly, . Éd, and N. J. Totowa, Marijuana and the cannabinoids, 2007.
DOI : 10.1007/978-1-59259-947-9

A. A. Izzo, F. Borrelli, R. Capasso, V. D. Marzo, and E. R. Mechoulam, Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb, Trends in Pharmacological Sciences, vol.30, issue.10, pp.515-527, 2009.
DOI : 10.1016/j.tips.2009.07.006

I. Lastres-becker and J. Fernandez-ruiz, « An overview of Parkinson's disease and the cannabinoid system and possible benefits of cannabinoid-based treatments, Curr. Med. Chem, vol.13, pp.30-3705, 2006.

J. Fernández-ruiz, The endocannabinoid system as a target for the treatment of motor dysfunction, British Journal of Pharmacology, vol.276, issue.1074, pp.1029-1040, 2009.
DOI : 10.1111/j.1476-5381.2008.00088.x

J. M. Walker, S. M. Huang, N. M. Strangman, K. Tsou, and M. C. , Sañudo-Peña, « Pain modulation by release of the endogenous cannabinoid anandamide, Proc. Natl. Acad. Sci, pp.12198-12203, 1999.

J. D. Richardson, S. Kilo, and K. M. Hargreaves, Cannabinoids reduce hyperalgesia and inflammation via interaction with peripheral CB1 receptors, Pain, vol.75, issue.1, pp.111-119, 1998.
DOI : 10.1016/S0304-3959(97)00213-3

J. ?ev?ík and K. Ma?ek, « Potential role of cannabinoids in Parkinson's disease », Drugs Aging, vol.16, issue.6, pp.391-395, 2000.

«. Laboratoires and A. Ltée, Monographie de produit pour Marinol, 2010.

M. A. Huestis, Human Cannabinoid Pharmacokinetics, Human cannabinoid pharmacokinetics, pp.1770-1804, 2007.
DOI : 10.1002/cbdv.200790152

D. J. Harvey, Absorption, Distribution, and Biotransformation of the Cannabinoids, Marihuana and medicine, pp.91-103, 1999.
DOI : 10.1007/978-1-59259-710-9_10

M. Widman, I. Nilsson, S. Agurell, H. Borg, and B. Granstrand, « Plasma protein binding of 7-hydroxy-1-tetrahydrocannabinol: an active 1-tetrahydrocannabinol metabolite, J Pharm Pharmacol, pp.453-460

G. G. Nahas, The pharmacokinetics of THC in fat and brain: resulting functional responses to marihuana smoking, Human Psychopharmacology: Clinical and Experimental, vol.46, issue.3, pp.247-255, 2001.
DOI : 10.1002/hup.258

M. E. Wall and M. Perez-reyes, -Tetrahydrocannabinol and Related Cannabinoids in Man, The Journal of Clinical Pharmacology, vol.32, issue.S1, pp.178-189, 1981.
DOI : 10.1002/j.1552-4604.1981.tb02594.x

URL : https://hal.archives-ouvertes.fr/hal-00480375

«. Dronabinol-capsule-[-akorn and I. ». , En ligne] Disponible sur: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a0409d82-a61e-4b9e-8717- ced299ccedb2, Consulté le, pp.20-2014

R. C. , R. P. Sheskey, and . Quinn-e-m, Handook of pharmaceutical excipients, 2009.

W. Pascal, Pharmacie Galénique : formulation et technologie pharmaceutique. 2ème édition, 2ème édition

J. Després, A. Golay, and E. L. Sjöström, Effects of Rimonabant on Metabolic Risk Factors in Overweight Patients with Dyslipidemia, New England Journal of Medicine, vol.353, issue.20, pp.20-2121, 2005.
DOI : 10.1056/NEJMoa044537

«. Ansm, Agence nationale de sécurité du médicament et des produits de santé ». [En ligne]. Disponible sur: http://ansm.sante, Consulté le, pp.29-2014

R. Prescrire and «. Rimonabant, suspension d'AMM annoncée, p.897, 2008.

R. Christensen, P. K. Kristensen, E. M. Bartels, and H. Bliddal, Astrup, « Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials », The Lancet, pp.9600-1706, 2007.

O. Algalarrondo, « De la consommation au sevrage (cannabis, cocaïne, amphétamines, héroïne), en milieu libre ou en milieu carcéral : prises en charge et rôle du pharmacien d'officine, 2014.

«. Un-projet-de-loi-de-légalisation-du-cannabis-en-france, !. Du-growshop-alchimia, and ». , Disponible sur: https://www.alchimiaweb.com/blogfr/projet-loilegalisation-cannabis-france, Consulté le, pp.27-2015

«. ». Cannabis-synthèse-des-connaissances-ofdt, En ligne] Disponible sur: http://www.ofdt.fr/produits-et-addictions, Consulté le, pp.24-2015

«. Sur and L. Route, le cannabis est une drogue mortelle Campagne d'information et de sensibilisation des jeunes / Publications presse / Espace presse -Sécurité routière | Tous responsables ». [En ligne] Disponible sur: http://www.securiteroutiere.gouv.fr/medias/espace-presse/publications-presse/sur-la-route-le-cannabis-estune-drogue-mortelle-campagne-d-information-et-de-sensibilisation-des-jeunes, pp.22-2015